Asset
DACLIZUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02881567 | phase3 | terminated | 2017-04-18 | 2018-09-12 | Biogen | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761029 | BLA | Biogen Inc. |
Marketed products (2)
- ZINBRYTA
- Zinbryta